First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Autor: Renaud Descourt, Laurent Greillier, Maurice Perol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Radj Gervais, Rémi Veillon, Sabine Vieillot, Florian Guisier, Marie Marcq, Grégoire Justeau, Laurence Bigay-Game, Marie Bernardi, Pierre Fournel, Hélène Doubre, Julian Pinsolle, Karim Amrane, Christos Chouaïd, Chantal Decroisette
Přispěvatelé: Service d'Oncologie Thoracique (BREST - ICH), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Institut de cancérologie et hématologie, CHU Marseille, Aix Marseille Université (AMU), Hospices Civils de Lyon (HCL), Centre Léon Bérard [Lyon], Service de pneumologie [Rennes] = Pneumology [Rennes], CHU Pontchaillou [Rennes], CH, Mantes-La-Jolie, Centre Hospitalier de Villefranche sur Saône, Partenaires INRAE, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Bordeaux [Bordeaux], Catalan Institute of Oncology [Perpignan], Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Hôpital Foch [Suresnes], Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), IMRB - CEPIA/'Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Rok vydání: 2022
Předmět:
safety
Cancer Research
geriatric assessment
efficacy
MESH: Neoplasms
Glandular and Epithelial
Immunology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Guidelines
Thymic carcinoma
Non-small cell lung cancer
Chemotherapy
Immunology and Allergy
MESH: Cohort Studies
[STAT.AP]Statistics [stat]/Applications [stat.AP]
Advanced stage
MESH: Humans
MESH: Thymoma
Radiotherapy
toxicity
Brain metastases
MESH: Retrospective Studies
Real-world study
MESH: Neoplasm Staging
targeted therapy
[INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation
MESH: Prospective Studies
lung cancer
quality of life
Oncology
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Surgery
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Pembrolizumab
[PHYS.PHYS.PHYS-DATA-AN]Physics [physics]/Physics [physics]/Data Analysis
Statistics and Probability [physics.data-an]
MESH: Thymus Neoplasms
Zdroj: Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 2023, 72 (1), pp.91-99. ⟨10.1007/s00262-022-03232-2⟩
ISSN: 1432-0851
0340-7004
DOI: 10.1007/s00262-022-03232-2
Popis: Few real-world data are available in patients with advanced metastatic non-small cell lung cancer (NSCLC) treated with first-line immunotherapy, particularly in those with brain metastases at treatment initiation.This was a national, retrospective, multicenter study that consecutively included all patients with PD-L1-positive (tumor proportion score ≥ 50%) advanced NSCLC who initiated first-line treatment with pembrolizumab as a single agent between May 2017 (date of availability of pembrolizumab in this indication in France) to November 22, 2019 (approval of the pembrolizumab-chemotherapy combination). Data were collected from medical records with local response assessment.The cohort included 845 patients and 176 (20.8%) had brain metastases at diagnosis. There were no significant differences in outcomes for patients with and without brain metastases: 9.2 (95% CI 5.6-15) and 8 (95% CI 6.7-9.2, p = 0.3) months for median progression-free survival (PFS) and, 29.5 (95% CI 17.2-NA) and 22 (95% CI 17.8-27.1, p = 0.3) months for median overall survival (OS), respectively. Overall response rates were 47% and 45% in patients with and without cerebral metastases. In multivariate analysis, performance status 2-4 vs. 0-1 and neutrophil-to-lymphocyte ratio ≥ 4 vs. 4 were the main independent negative factors for OS; brain metastasis was not an independent factor for OS.In this large multicenter cohort, nearly 20% of patients initiating pembrolizumab therapy for advanced NSCLC had cerebral metastases. There was no significant difference in response rates, PFS and OS between patients with and without brain metastases.
Databáze: OpenAIRE
Externí odkaz: